查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933885

核酸萃取市场（依产品类型、萃取技术、样品类型和应用划分）－全球预测，2026-2032年

Nucleic Acid Extraction Market by Product Type, Extraction Technique, Sample Type, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年核酸萃取市场规模将达到 41.2 亿美元，到 2026 年将成长至 44.3 亿美元，到 2032 年将达到 74.8 亿美元，年复合成长率为 8.89%。

关键市场统计数据
基准年 2025 41.2亿美元
预计年份：2026年 44.3亿美元
预测年份 2032 74.8亿美元
复合年增长率 (%) 8.89%

本文全面介绍了核酸萃取作为分子工作流程基础的重要性，以及技术、操作和监管要求如何影响各领域解决方案的选择。

核酸萃取是一项基础的实验室操作，它为可靠的下游分子分析（例如基因测序、聚合酵素链锁反应(PCR) 以及越来越多的诊断和研究检测）提供了基础。其重要性源于从日益多样化和复杂的样本基质中分离高品质 DNA 和 RNA 的需求，因为纯度和完整性决定了后续工作流程的敏感度、特异性和可重复性。因此，实验室相关人员优先考虑那些能够平衡通量、自动化程度、样本相容性和监管稳健性的方法，以满足临床诊断、转化研究和药物发现的技术要求。

自动化、先进化学技术、互通性和基于服务的模式如何共同重塑生命科学领域的核酸提取能力和采购重点

核酸萃取领域正经历多项技术和操作方面的变革，这些变革正在重新定义实验室对萃取解决方案的需求。其中最主要的变化是向自动化和高通量能力的转变，这使得临床检查室和中心实验室能够在保持检测性能的同时扩大检测规模。与自动化并行的是，以微珠为基础的化学方法也因其稳健性和对各种检体类型的适应性而备受关注。它既支援可轻鬆整合到机器人系统中的顺磁性多粒子珠系统，也支援用于特殊手动处理的非顺磁性磁珠工作流程。

评估2025年美国关税环境如何推动核酸提取生态系统的供应链重组、采购调整和策略性近岸外包。

美国在2025年实施的新关税，使得核酸萃取设备、试剂及相关耗材的全球供应链变得更加复杂。关税导致进口零件和成品成本上升，迫使製造商和经销商重新评估其筹资策略，许多企业正在加速供应商多元化，并评估近岸外包和国内生产的可能性，以降低风险。这些策略性因应措施反映了企业在成本优化和供应链韧性之间寻求平衡的更广泛趋势，并将对采购週期和合约结构产生直接影响。

深度細項分析揭示了产品类型、提取技术、应用、最终用户和检体分类如何决定技术需求和商业化策略。

细分市场层面的趋势揭示了不同产品类型、萃取技术、应用、终端用户和样品类别之间截然不同的性能和应用模式，每种模式都需要独特的技术解决方案和商业化方法。产品系列涵盖仪器、试剂组和服务。仪器种类繁多，从专为低通量实验室设计的桌上型系统到用于集中检测机构的高通量平台，应有尽有。试剂组依工作流程自动化程度的不同，提供自动化和手动两种形式。服务包括客製化萃取服务和样品製备服务，旨在帮助不具备内部能力的客户。萃取技术同样多种多样。以微珠为基础法具有灵活性，可使用各种顺磁性磁珠轻鬆整合到自动化工作流程中，也可使用非顺磁性磁珠进行专门的手动通讯协定。沉淀法分为醇基沉淀法和盐基沉淀法，二者在纯度和产率方面各有优劣。旋转柱系统采用聚合物基膜或硅胶膜，针对不同的结合和清洁性能进行了最佳化。

区域分析表明，主要全球市场中不同的管理体制、基础设施成熟度和供应链优先事项如何导致不同的采用模式。

区域趋势揭示了美洲、欧洲、中东和非洲以及亚太市场在产品应用路径和投资重点方面存在的差异化驱动因素和限制因素。在美洲，强劲的临床诊断需求和成熟的研究生态系统推动了对自动化和整合工作流程的投资，而采购决策则受到报销政策和医疗基础设施差异的影响。作为重要的研发和临床检测中心，美国高度重视监管检验、快速结果报告以及与检查室IT系统的互通性，因此更倾向于选择性能可靠且售后服务完善的仪器和试剂组。

竞争评估重点阐述了智慧财产权、平台套件合作伙伴关係、区域服务网络和监管合规如何创造可持续的商业性优势。

领先供应商之间的竞争动态凸显了技术差异化、策略伙伴关係和服务整合的重要性。那些投资于强大的智慧财产权组合（尤其是在萃取化学技术和仪器自动化介面方面）的市场参与企业，能够透过与下游分析平台的紧密整合来巩固自身地位。仪器製造商和试剂开发人员之间的合作已成为一种普遍趋势，预先检验的试剂盒和平台组合能够减轻客户的检验负担，并加速其在临床和研究环境中的应用。此外，越来越多的公司正在探索以服务主导的交付模式，为寻求承包解决方案和扩充性但又不想进行大量资本投入的机构提供客製化的萃取解决方案和工作流程管理。

製造商和供应商提升产品适应性、供应弹性、服务品质和临床检验以实现可持续成长的实用策略

为了掌握核酸萃取领域不断增长的机会，产业领导者应采取多管齐下的策略，平衡技术创新、供应链韧性和以客户为中心的服务模式。优先发展模组化自动化架构，使其既能支援桌上型操作的柔软性，扩充性的高通量配置需求，从而实现跨领域的吸引力，从就地检验实验室到集中式检测中心均能适用。同时，也应投资于自动化试剂盒和手动试剂盒之间的试剂相容性，以减少客户锁定，并促进检查室在工作流程模式变更时实现平稳过渡。

本报告的调查方法说明一手访谈、第二手资料检验、细分调整和详细的检验流程，以确保提供可操作且可靠的市场洞察。

本报告的研究融合了定性访谈、文献综述和系统性细分映射，以确保分析的严谨性和透明度。主要数据是透过对来自临床、研究和商业机构的检查室经理、采购人员、研发科学家和法规专家进行结构化和半结构化访谈收集的，旨在提供关于营运挑战、采购标准和技术偏好的实证观点。包括同侪审查文献、技术白皮书、法规指导文件和供应商技术规格第二手资料，检验并强化了访谈结果。

简明扼要地总结了技术进步、营运韧性和策略伙伴关係将如何决定核酸萃取领域的长期领导地位。

核酸萃取仍然是现代分子生物学、诊断学和治疗研发中至关重要的基础技术。自动化、先进的萃取化学技术和以服务为导向的供应模式的相互作用，正在催生一个以技术性能、互通性和供应链韧性为长期成功关键的市场。实验室和生命科学机构日益寻求能够处理从血浆、血清到福马林固定石蜡包埋（FFPE）组织等多种检体类型的解决方案，同时还要能够无缝整合到更广泛的实验室工作流程和品管框架中。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的核酸萃取市场

  • 装置
    • 桌上型系统
    • 高通量系统
  • 试剂组
    • 自动化套件
    • 手册套件
  • 服务
    • 客製化提取服务
    • 样品製备服务

第九章 核酸萃取市场（依萃取技术划分）

  • 以微珠为基础的
    • 高磁性珠子
    • 顺磁性珠子
  • 降水法
    • 酒精沉淀
    • 盐析法
  • 旋转柱
    • 聚合物基膜
    • 二氧化硅膜

第十章 依检体类型分類的核酸萃取市场

  • 血液样本
    • 电浆
    • 血清
    • 全血
  • 细胞样本
    • 培养细胞
    • 原代细胞
  • 组织样本
    • FFPE组织
    • 新鲜纸巾

第十一章 核酸萃取市场：依应用领域划分

  • 临床诊断
    • 基因检测
    • 传染病检查
  • 法医分析
    • 犯罪现场调查
    • 亲子鑑定
  • 药物研发
    • 生物标誌物开发
    • 药物发现
  • 研究
    • 基因组研究
    • 转录组学调查

第十二章 核酸萃取市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 核酸萃取市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国核酸萃取市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国核酸萃取市场

第十六章 中国核酸萃取市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Analytik Jena AG
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Bioneer Corporation
  • Danaher Corporation
  • Eppendorf AG
  • Hamilton Company
  • Hologic, Inc.
  • Illumina, Inc.
  • Kurabo Biomedical
  • LGC Biosearch Technologies
  • Lucigen Corporation
  • Macherey-Nagel GmbH & Co. KG
  • Merck KGaA
  • New England Biolabs
  • Norgen Biotek Corp.
  • Omega Bio-Tek, Inc.
  • PerkinElmer, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Takara Bio Inc.
  • Tecan Group Ltd
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation
Product Code: MRR-C36616F699A3

The Nucleic Acid Extraction Market was valued at USD 4.12 billion in 2025 and is projected to grow to USD 4.43 billion in 2026, with a CAGR of 8.89%, reaching USD 7.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.12 billion
Estimated Year [2026] USD 4.43 billion
Forecast Year [2032] USD 7.48 billion
CAGR (%) 8.89%

Comprehensive introduction to why nucleic acid extraction underpins molecular workflows and how technical, operational, and regulatory demands shape solution selection across sectors

Nucleic acid extraction serves as the foundational laboratory process that enables reliable downstream molecular analyses, including genomic sequencing, polymerase chain reaction, and a growing array of diagnostic and research assays. Its centrality stems from the need to isolate high-quality DNA and RNA from increasingly diverse and complex sample matrices, where purity and integrity determine the sensitivity, specificity, and reproducibility of subsequent workflows. Laboratory stakeholders therefore prioritize methods that balance throughput, automation, sample compatibility, and regulatory robustness to meet the technical demands of clinical diagnostics, translational research, and pharmaceutical discovery.

Operational realities are shaping how extraction solutions are evaluated and adopted. Laboratories that process clinical specimens must contend with chain-of-custody requirements and validated workflows, while academic and industrial research groups often require flexible protocols that accommodate novel sample types and experimental designs. Additionally, the integration of extraction platforms with laboratory information systems and automation suites is driving preference for modular solutions that support seamless data capture and traceability. As a result, product portfolios span bench-top instruments and high-throughput systems, reagent kits optimized for manual and automated processing, and a spectrum of services that include custom extraction and sample preparation support.

End users differ in their demands, whether focused on blood-derived biomarkers, cultured cell inputs, or formalin-fixed paraffin-embedded tissue, which necessitates a nuanced appreciation of sample-specific extraction chemistries and device designs. Emerging applications, such as single-cell and transcriptomic studies, place heightened emphasis on low-input recovery and minimal degradation, while forensic and public health contexts emphasize robustness across degraded or low-abundance samples. Collectively, these vectors of technical need and operational constraint frame a market where innovation is driven by a combination of scientific rigor, workflow efficiency, and regulatory compliance.

How automation, advanced chemistries, interoperability, and service-based models are jointly reshaping nucleic acid extraction capabilities and procurement priorities across the life sciences

The landscape for nucleic acid extraction is evolving through several convergent technological and operational shifts that are redefining what laboratories expect from extraction solutions. Foremost among these shifts is the move toward automation and high-throughput capacity, which enables clinical laboratories and central testing facilities to scale testing volumes while preserving assay performance. Alongside automation, magnetic bead-based chemistries are gaining traction due to their robustness and adaptability across sample types, supporting both paramagnetic bead systems that integrate readily with robotics and non-paramagnetic bead workflows for specialized manual handling.

Another transformative change is the refinement of membrane and column chemistries. Advances in polymer-based and silica membrane technologies have improved nucleic acid binding efficiency and inhibitor removal, which benefits downstream applications like next-generation sequencing and diagnostic PCR. These developments are complemented by reagent kit innovations that target both automated platforms and manual protocols, ensuring laboratories of varying resource levels can match extraction performance to operational constraints.

Interoperability across the lab ecosystem is also reshaping procurement decisions. Instruments and reagent kits that align with laboratory information management systems, sample tracking protocols, and quality-control frameworks command preference because they reduce integration friction and support compliance. In parallel, an expanded role for service providers has emerged; custom extraction services and specialized sample-preparation offerings now support organizations that lack in-house capacity or require bespoke protocols for complex matrices. Taken together, these shifts are creating an environment in which agility, scalability, and integration capability distinguish leading solutions, and where the pace of incremental innovation is accelerating in response to both scientific advances and evolving healthcare priorities.

Assessment of how the 2025 United States tariff landscape is driving supply chain realignment, procurement adaptation, and strategic nearshoring across nucleic acid extraction ecosystems

The introduction of new tariff measures in the United States in 2025 has introduced a layer of complexity across global supply chains for nucleic acid extraction instruments, reagents, and ancillary consumables. Tariff-related cost increases for imported components and finished products have prompted manufacturers and distributors to reassess sourcing strategies, with many accelerating supplier diversification efforts and evaluating nearshoring or domestic manufacturing to mitigate exposure. These strategic responses reflect a broader recalibration of supply resilience versus cost optimization that has immediate implications for procurement timelines and contractual arrangements.

Tariffs have also influenced pricing dynamics along the distribution channel. End users report lengthened negotiations as suppliers seek to absorb some tariff impacts while preserving margins and quality standards. The pressure is most acute for capital-intensive bench-top and high-throughput instruments where component tariffs cascade into higher list prices or extended lead times as manufacturers retool procurement. Reagent kits, particularly those reliant on specialized enzymes and proprietary chemistries sourced internationally, have seen tighter inventory management practices as distributors prioritize continuity of supply for critical clinical and research customers.

Policy-driven trade barriers have accelerated strategic partnerships and regional alliances, as vendors pursue mutually beneficial arrangements to secure component access and optimize logistics. In response, service providers offering custom extraction and sample-preparation capabilities are increasingly positioning themselves as local partners to hedge tariff-related uncertainty, enabling laboratories to maintain continuity without committing to large capital expenditures. Regulatory agencies and accreditation bodies are simultaneously adapting guidance on supply chain documentation and validation requirements, emphasizing transparency around sourcing and change control for validated workflows. Ultimately, the tariff environment is catalyzing structural adjustments across procurement, manufacturing footprint, and service models, making supply chain resilience a critical component of vendor evaluation and institutional risk management.

Deep segmentation insight revealing how product types, extraction techniques, applications, end users, and sample classes determine technical requirements and commercialization strategies

Segment-level dynamics reveal nuanced performance and adoption patterns across product types, extraction techniques, applications, end users, and sample categories, each demanding distinct technical solutions and commercialization approaches. Product portfolios span instruments, reagent kits, and services, where instruments encompass bench-top systems tailored for lower throughput laboratories and high-throughput platforms designed for centralized testing facilities, reagent kits differentiate between automated and manual formats to suit varying workflow automation degrees, and services include both custom extraction engagements and sample-preparation offerings that support clients without in-house capacity. Extraction technique choices are similarly diverse: magnetic bead-based methods provide adaptability with paramagnetic bead variants that readily integrate into robotic workflows and non-paramagnetic options used in specialized manual protocols, precipitation approaches divide into alcohol-based and salt-based chemistries offering different purity and yield trade-offs, and spin column systems rely on either polymer-based or silica membranes optimized for distinct binding and wash characteristics.

Application-driven requirements strongly influence product configuration and support models. Clinical diagnostics demand validated procedures for genetic testing and infectious disease testing with strict quality controls and traceability, forensic analysis prioritizes workflows capable of handling degraded or limited samples for crime scene investigation and paternity testing, pharmaceutical development focuses on reproducible extraction for biomarker discovery and drug discovery pipelines, and research settings require flexibility for genomics and transcriptomics research that may entail low-input or single-cell workflows. End users reflect a spectrum of operational contexts: academic and research institutes encompass research centers and universities with diverse protocol needs and budgetary constraints, diagnostic laboratories include both central labs and point-of-care facilities with differing throughput profiles, hospitals and clinics operate across private clinics and public hospitals where regulatory and procurement environments vary, and pharmaceutical and biotechnology companies consist of large-scale pharmaceutical enterprises and more agile biotech firms pursuing translational and discovery programs.

Sample-type considerations further shape product and service offerings. Blood-derived inputs, including plasma, serum, and whole blood, require chemistries that preserve nucleic acid integrity while minimizing inhibitors; cell samples comprised of cultured cells and primary cells demand gentle lysis and efficient recovery to support downstream assays; and tissue samples present distinct challenges where FFPE tissue necessitates deparaffinization and damage reversal protocols, while fresh tissue benefits from rapid stabilization approaches. Vendors and service providers that align product capabilities and support services to these segmentation layers-offering validated protocols, modular instrument compatibility, and targeted training-are positioned to address a broad set of customer needs while differentiating through technical depth and operational support.

Regional analysis showing how distinct regulatory regimes, infrastructure maturity, and supply chain priorities drive differentiated adoption patterns across major global markets

Regional dynamics exhibit differentiated drivers and constraints that shape adoption pathways and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, strong clinical diagnostics demand and a mature research ecosystem incentivize investment in automation and integrated workflows, with procurement decisions influenced by reimbursement policies and healthcare infrastructure variability. The United States, as a significant R&D and clinical testing hub, emphasizes regulatory validation, rapid turnaround, and interoperability with laboratory IT systems, which in turn drives preference for instruments and reagent kits with proven performance and service backstops.

In Europe, Middle East & Africa, regulatory heterogeneity and a mix of centralized and decentralized laboratory networks create a market where modular solutions and adaptable service models gain traction. Compliance with regional standards and localized validation pathways is a prevailing consideration, and partnerships with regional distributors and service providers facilitate market entry and support. Across the Asia-Pacific region, rapid expansion of molecular diagnostics, a growing biotechnology sector, and increasing investment in genomic and public-health infrastructure are accelerating uptake of both high-throughput systems for centralized facilities and compact bench-top platforms for decentralized testing. Local manufacturing and regional supply chain development have also become strategic priorities in Asia-Pacific, reflecting efforts to balance cost-efficiency with supply reliability.

These regional differences inform vendor go-to-market strategies and service offerings. Companies that tailor their sales models, validation support, and training programs to regional regulatory frameworks and laboratory capabilities can capture opportunities more effectively. Furthermore, regional supply chain considerations, including proximity to component suppliers and logistics networks, influence lead times and total cost of ownership, prompting buyers and vendors alike to weigh local presence and service coverage as key criteria when selecting extraction platforms and reagent partners.

Competitive landscape assessment highlighting how intellectual property, platform-kit partnerships, regional service networks, and regulatory validation create enduring commercial advantages

Competitive dynamics among leading providers emphasize technological differentiation, strategic partnerships, and service integration. Market participants that invest in robust intellectual property portfolios, particularly around extraction chemistries and instrument automation interfaces, secure defensible positions by enabling tighter integration with downstream analytical platforms. Collaboration between instrument manufacturers and reagent developers is a recurring motif, as pre-validated kit-platform pairings reduce customer validation burdens and accelerate adoption across clinical and research settings. Additionally, an increasing number of companies pursue service-led offerings, supplying custom extraction solutions and managed workflows to institutions seeking turn-key capabilities or scalability without capital-intensive commitments.

Strategic activity also focuses on expanding geographic footprints and strengthening after-sales support networks to address regional service expectations and minimize instrument downtime. Partnerships with local distributors and the establishment of regional technical centers serve to shorten response times and enhance training capacity, which are critical value drivers for clinical laboratories operating under accreditation constraints. Investment in digital enablement, including remote diagnostics and predictive maintenance for instruments, further differentiates providers by improving uptime and facilitating more predictable operational planning for laboratory managers.

Finally, companies that demonstrate regulatory acumen and publish validation data for clinical contexts tend to build trust with diagnostic laboratories and healthcare systems. Transparent documentation of performance across sample types, adherence to change-control protocols, and provision of comprehensive training and quality-assurance resources increase vendor credibility and foster long-term relationships with high-value customers in pharmaceuticals, hospitals, and centralized testing facilities.

Practical strategic recommendations for manufacturers and suppliers to enhance product adaptability, supply resilience, service excellence, and clinical validation for sustainable growth

Industry leaders should pursue a multi-pronged strategy that balances technological innovation, supply chain resilience, and customer-centric service models to capture expanding opportunities in nucleic acid extraction. Prioritize modular automation architectures that support both bench-top flexibility and scalable high-throughput configurations, enabling cross-segment appeal from point-of-care labs to centralized testing centers. Concurrently, invest in reagent compatibility across automated and manual kits to reduce customer lock-in friction and to facilitate transitions between workflow modalities as laboratory needs evolve.

Strengthen supply chain strategies by diversifying suppliers, qualifying alternative component sources, and exploring regional manufacturing partnerships to mitigate tariff and logistics risks. Embed robust change-control and validation protocols into supply agreements to reassure customers and regulators about continuity of performance. Enhance service and support capabilities by establishing regional technical hubs, expanding training programs, and offering managed service options for customers preferring to outsource extraction workflows. These measures will reduce downtime risk and differentiate offerings on the basis of total operational value rather than price alone.

Finally, deepen scientific and clinical collaborations to generate peer-reviewed validation studies and real-world evidence across relevant sample types and applications. Collaborate with end users in academic, clinical, and pharmaceutical settings to co-develop protocols that address challenging matrices such as FFPE tissue or low-input single-cell samples. Use these partnerships to build compelling clinical utility narratives that facilitate adoption in regulated environments and to inform roadmap decisions that prioritize features delivering measurable laboratory efficiencies and assay improvements.

Rigorous research methodology detailing primary interviews, secondary evidence triangulation, segmentation alignment, and validation processes to ensure actionable and credible market intelligence

The research underpinning this report blends primary qualitative interviews, secondary literature synthesis, and methodical segmentation mapping to ensure analytical rigor and transparency. Primary inputs were obtained through structured and semi-structured interviews with laboratory managers, procurement leaders, R&D scientists, and regulatory specialists across clinical, research, and commercial organizations, providing grounded perspectives on operational challenges, procurement criteria, and technology preferences. Secondary material included peer-reviewed literature, technical white papers, regulatory guidance documents, and supplier technical specifications to validate and augment insights derived from interviews.

Data triangulation was applied across sources to corroborate thematic findings and to identify consistent patterns regarding technology adoption, sample-specific requirements, and regional procurement dynamics. The segmentation framework was developed iteratively, aligning product type, extraction technique, application, end-user, and sample-type categorizations with real-world purchasing and laboratory workflows to enhance relevance for decision-makers. Where appropriate, sensitivity analyses explored how external factors such as trade policy shifts and supply chain disruptions could alter vendor strategies and customer procurement behavior.

Limitations of the methodology are acknowledged, particularly the variability inherent in regional regulatory regimes and the rapid pace of technological innovation that can change vendor positioning between reporting cycles. The research mitigated these limitations through repeated validation with subject-matter experts and by focusing on durable structural trends rather than short-lived market fluctuations. All primary research participants were engaged under confidentiality terms, and qualitative findings were aggregated to preserve anonymity while delivering actionable insight.

Concise conclusion synthesizing how technological advances, operational resilience, and strategic partnerships will determine long-term leadership in nucleic acid extraction

Nucleic acid extraction remains a pivotal enabler of modern molecular biology, diagnostics, and therapeutic development. The interplay of automation, advanced extraction chemistries, and service-oriented delivery models has created a market where technical performance, interoperability, and supply chain resilience determine long-term success. Laboratories and life-science organizations are increasingly demanding solutions that can handle diverse sample types-from plasma and serum to FFPE tissue-while integrating seamlessly into broader laboratory workflows and quality frameworks.

At the vendor level, advantages accrue to those who couple platform innovation with reagent compatibility, robust regional service networks, and clear regulatory documentation. Meanwhile, policy shifts and trade measures emphasize the importance of strategic sourcing and regional manufacturing strategies to preserve supply continuity. For decision-makers, the priority is to select partners that not only meet immediate technical specifications but also provide the operational support and validation resources necessary for sustainable deployment across clinical, research, and industrial settings. The cumulative effect of these trends points toward an ecosystem that rewards agility, scientific depth, and customer-centric service models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Extraction Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Bench-Top Systems
    • 8.1.2. High-Throughput Systems
  • 8.2. Reagent Kits
    • 8.2.1. Automated Kits
    • 8.2.2. Manual Kits
  • 8.3. Services
    • 8.3.1. Custom Extraction Services
    • 8.3.2. Sample Preparation Services

9. Nucleic Acid Extraction Market, by Extraction Technique

  • 9.1. Magnetic Bead Based
    • 9.1.1. Non-Paramagnetic Beads
    • 9.1.2. Paramagnetic Beads
  • 9.2. Precipitation
    • 9.2.1. Alcohol Precipitation
    • 9.2.2. Salt Precipitation
  • 9.3. Spin Column
    • 9.3.1. Polymer-Based Membrane
    • 9.3.2. Silica Membrane

10. Nucleic Acid Extraction Market, by Sample Type

  • 10.1. Blood Samples
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Cell Samples
    • 10.2.1. Cultured Cells
    • 10.2.2. Primary Cells
  • 10.3. Tissue Samples
    • 10.3.1. FFPE Tissue
    • 10.3.2. Fresh Tissue

11. Nucleic Acid Extraction Market, by Application

  • 11.1. Clinical Diagnostics
    • 11.1.1. Genetic Testing
    • 11.1.2. Infectious Disease Testing
  • 11.2. Forensic Analysis
    • 11.2.1. Crime Scene Investigation
    • 11.2.2. Paternity Testing
  • 11.3. Pharmaceutical Development
    • 11.3.1. Biomarker Development
    • 11.3.2. Drug Discovery
  • 11.4. Research
    • 11.4.1. Genomics Research
    • 11.4.2. Transcriptomics Research

12. Nucleic Acid Extraction Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Extraction Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Extraction Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nucleic Acid Extraction Market

16. China Nucleic Acid Extraction Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Analytik Jena AG
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. BioMerieux SA
  • 17.9. Bioneer Corporation
  • 17.10. Danaher Corporation
  • 17.11. Eppendorf AG
  • 17.12. Hamilton Company
  • 17.13. Hologic, Inc.
  • 17.14. Illumina, Inc.
  • 17.15. Kurabo Biomedical
  • 17.16. LGC Biosearch Technologies
  • 17.17. Lucigen Corporation
  • 17.18. Macherey-Nagel GmbH & Co. KG
  • 17.19. Merck KGaA
  • 17.20. New England Biolabs
  • 17.21. Norgen Biotek Corp.
  • 17.22. Omega Bio-Tek, Inc.
  • 17.23. PerkinElmer, Inc.
  • 17.24. Promega Corporation
  • 17.25. QIAGEN N.V.
  • 17.26. Roche Diagnostics International AG
  • 17.27. Takara Bio Inc.
  • 17.28. Tecan Group Ltd
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. Zymo Research Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID EXTRACTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID EXTRACTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEIC ACID EXTRACTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEIC ACID EXTRACTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BENCH-TOP SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BENCH-TOP SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BENCH-TOP SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY HIGH-THROUGHPUT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY HIGH-THROUGHPUT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY HIGH-THROUGHPUT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY AUTOMATED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY AUTOMATED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY AUTOMATED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MANUAL KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MANUAL KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MANUAL KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CUSTOM EXTRACTION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CUSTOM EXTRACTION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CUSTOM EXTRACTION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY NON-PARAMAGNETIC BEADS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY NON-PARAMAGNETIC BEADS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY NON-PARAMAGNETIC BEADS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PARAMAGNETIC BEADS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PARAMAGNETIC BEADS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PARAMAGNETIC BEADS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY ALCOHOL PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY ALCOHOL PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY ALCOHOL PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SALT PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SALT PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SALT PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY POLYMER-BASED MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY POLYMER-BASED MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY POLYMER-BASED MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SILICA MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SILICA MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SILICA MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CULTURED CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CULTURED CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CULTURED CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FFPE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FFPE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FFPE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FRESH TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FRESH TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FRESH TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CRIME SCENE INVESTIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CRIME SCENE INVESTIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY CRIME SCENE INVESTIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PATERNITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PATERNITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PATERNITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GENOMICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GENOMICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TRANSCRIPTOMICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TRANSCRIPTOMICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY TRANSCRIPTOMICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL NUCLEIC ACID EXTRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY CELL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY FORENSIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN NUCLEIC ACID EXTRACTION MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 303. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 306. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 307. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 308. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY EXTRACTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 309. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY MAGNETIC BEAD BASED, 2018-2032 (USD MILLION)
  • TABLE 310. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 311. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY SPIN COLUMN, 2018-2032 (USD MILLION)
  • TABLE 312. GCC NUCLEIC ACID EXTRACTION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (